University of Washington’s Baker Lab and Google DeepMind redefine protein science, paving the way for AI-driven biotherapeutics
ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutics research and technology company, today celebrates the recent Nobel Prize in Chemistry awarded to David Baker of the University of Washington , Seattle, Washington, USA, “for computational protein design”, and jointly with Demis Hassabis and John M. Jumper of Google DeepMind, London, UK, “for protein structure prediction” . This distinction highlights the essential role of computational tools and AI in advancing our understanding of protein structures, principles that are at the heart of IPA’s research initiatives. These achievements validate the methodologies underlying IPA’s proprietary AI model, LENSaiwhich leverages similar computational and AI approaches to innovate drug discovery.
“As IPA continues to optimize LENSaiour proprietary AI platform, we remain committed to leveraging cutting-edge technologies to unravel the complex interactions between proteins. AlphaFold’s Nobel Prize recognition highlights the growing importance of AI in scientific breakthroughs. At ImmunoPrecise Antibodies, we are committed to integrating advanced AI technologies into our workflows, which not only amplifies our capabilities in drug development, but also aligns with our mission to stay at the forefront innovative biotherapeutic solutions,” said Dr. Jennifer Bath, CEO, ImmunoPrecise Antibodies.
At IPA, the integration of AlphaFold, an open-access AI tool developed by Google DeepMind, into our drug discovery processes has revolutionized the way we approach complex biological challenges. By leveraging AlphaFold’s open-access protein structure predictions, IPA improves antibody design and optimization, making significant progress in developing treatments for diseases that were previously thought to be intractable.
“Our HYFT technology amplifies the power of AlphaFold and other fundamental AI models by providing deeper biological context. HYFT identifies key functional and structural motifs in protein sequences, improving the accuracy of AlphaFold predictions and expanding its application in drug discovery,” said Dr. Van Hyft, Chief Innovation Officer, ImmunoPrecise Antibodies. “This combination allows us to push the boundaries in biotherapeutic development, accelerating the move from prediction to solution. »
For detailed information about AlphaFold’s impact on drug discovery and its integration into IPA’s technology stack, read its subsidiary BioStrand’s blog post: Explained: A Brief Look Into AlphaFold 2.
In the future, IPA wants to expand partnerships within academia and industry to continue exploring the potential of AI in the development of new therapies. IPA invites interested parties to join in advancing the application of LENSaifor a future in which diseases are not simply treated, but understood and avoided.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multiomics modeling and complex artificial intelligence systems through a series of proprietary and patented technologies. Recognized for its ability to address highly complex industrial challenges, the company has a suite of capabilities integrated end-to-end to support the development of therapeutic antibodies. IPA has several subsidiaries in North America and Europe, namely Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) BV (collectively, the “IPA Family”).
Forward-looking statements
This press release contains forward-looking statements within the meaning of applicable securities laws in the United States and Canada. Forward-looking statements are often identified by the use of words such as “expects”, “estimates”, “intends”, “plans” or “anticipates”, or variations of these words and expressions, or indicate that certain actions, events or results “may”, “should”, “could” or “may” be taken, occur, or be achieved. Forward-looking statements include, but are not limited to, statements relating to computational and AI approaches to innovation in drug discovery. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that such statements are based on a combination of facts and factors currently known to us and our expectations for the future, of which we do not we can’t be certain. Our actual future results may differ materially from what we expect due to factors largely beyond our control, including risks and uncertainties related to market and other conditions and the impact general economic, industrial or political conditions in the United States, Canada or abroad. The reader is encouraged to consult our quarterly and annual filings with the Canadian and United States securities commissions for further information on risks and uncertainties. These forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to revise or update any forward-looking statements for any reason, even if new information becomes available. ‘future.
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements stated herein to differ materially from any future results, performance or achievements expressed or implied. -understood in the forward-looking statements. Actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the Company’s Annual Report on Form 20-F for the fiscal year ended April 30, 2024 (available at the company’s SEDAR+ profile at www.sedar.ca and the EDGAR profile at www.sec.gov/edgar). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied in the forward-looking statements contained in this press release. The reader is therefore cautioned not to place undue reliance on the forward-looking statements contained in this press release. The forward-looking statements contained in this press release are made as of the date of this press release and, therefore, are subject to change after this date. The Company undertakes no obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.
The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the press release is that of the press release in its original language. The translation must always be compared with the source text, which will set a precedent.
View the source version on businesswire.com: https://www.businesswire.com/news/home/20241010289288/fr/
